Step 1: Recognise that a pregnant HIV patient receives a standard combination ART skeleton: dual NRTI backbone plus one anchor agent. The options here are different dual-NRTI backbones, so judge each for acceptability in pregnancy.
Step 2: $TDF/FTC$ (tenofovir disoproxil fumarate plus emtricitabine) is a guideline-preferred fixed-dose backbone in pregnancy.
Step 3: $TDF/3TC$ (tenofovir plus lamivudine) is interchangeable with the above, with extra caution when renal function is impaired.
Step 4: $ABC/3TC$ (abacavir plus lamivudine) is also preferred provided HLA-B*5701 screening is negative to avoid hypersensitivity. All three use NRTIs that transfer across the placenta, which is desirable for fetal protection.
Step 5: As every listed backbone is a legitimate preferred choice, no single one can be excluded.
\[\boxed{\text{All}}\]